GTS Securities’s Rhythm Pharmaceuticals RYTM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-6,900
Closed -$283K – 4390
2024
Q2
$283K Sell
6,900
-4,300
-38% -$172K ﹤0.01% 3179
2024
Q1
$485K Buy
11,200
+6,200
+124% +$271K ﹤0.01% 2609
2023
Q4
$230K Sell
5,000
-18,100
-78% -$571K ﹤0.01% 3450
2023
Q3
$530K Buy
+23,100
New +$517K ﹤0.01% 2565

Other funds holding RYTM

GTS Securities's RYTM Position: Q3 2026 in Review

GTS Securities opened a new position in Rhythm Pharmaceuticals (RYTM) in Q3 2026: 2,203 shares worth $210K. The stake represents ﹤0.01% of the portfolio and ranks #1518 among its holdings. This is a return to the name: GTS Securities previously reported a position in RYTM as recently as Q2 2024.

GTS Securities first reported a position in RYTM in Q2 2024 and has held it in 2 quarters since. The position peaked at $950K in Q2 2024. 328 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

  • GTS Securities held 2,203 shares of Rhythm Pharmaceuticals worth $210K as of Q3 2026.
  • Rhythm Pharmaceuticals was a new GTS Securities position in Q3 2026.
  • Rhythm Pharmaceuticals made up ﹤0.01% of GTS Securities's portfolio in Q3 2026, its #1518 holding.
  • GTS Securities first reported a position in Rhythm Pharmaceuticals in Q2 2024 and has held it in 2 quarters since.
  • GTS Securities's Rhythm Pharmaceuticals position peaked at $950K in Q2 2024.
  • 328 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on GTS Securities's 13F filing for Q3 2026, filed 16 Nov 2026.